Marinus Pharmaceuticals Inc
MRNS.O- Latest Trade
- trading lower4.8USD
- Change
- -0.11
- % Change
2.24%Negative
- Day Range
- 4.61 - 4.88
- 52-Week Range
- 3.97 - 19.38
As of Jun 29 2022. Values delayed up to 15 minutes
- Previous Close
- 4.91
- Open
- 4.85
- Volume
- 188,154.00
- 3 Month Average Trading Volume
- 7.22
- Shares Out (Mil)
- 37.14
- Market Cap
- 189.79
- Forward P/E
- -2.12
- Dividend Yield
- -99,999.99
Key Statistics
1.5 mean rating - 10 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 6.85
- Price To Book (Quarterly)
- 5.26
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 173.07
- Long Term Debt/Equity (Quarterly)
- 173.07
- Return On Investment (TTM)
- -76.14
- Return On Equity (TTM)
- -66.26
2021 (millions USD)
About Marinus Pharmaceuticals Inc
Company Information
Marinus Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The Company’s lead product candidate is ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), which is developed for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD). Ganaxolone is a methylated analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A (GABAA) receptors, a target known for its anti-seizure, antidepressant, and anxiolytic potential.
Address
Three Radnor Corporate Center 100 Matsonford Rd, Suite 304RADNOR, PA
19087
United States
Industry
Business Services
Executive Leadership
- Nicole Vitullo
- Independent Chairman of the board
- Scott N. Braunstein
- President, Chief Executive Officer, Director
- Steven Pfanstiel
- Chief Financial Officer, Treasurer
- Martha E. Manning
- Vice President, General Counsel, Corporate Secretary
- Joseph Hulihan
- Chief Medical Officer
- Santiago Arroyo
- Independent Director
- Charles Austin
- Independent Director
- Michael R. Dougherty
- Independent Director
- Elan Z. Ezickson
- Independent Director
- Seth H. Z. Fischer
- Independent Director
- Timothy M. Mayleben
- Independent Director
- Saraswathy V. Nochur
- Independent Director
Latest News
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,813.70 | -- |
| Copper | 694.25 | 1.57%Negative |
| Brent Crude Oil | 116.26 | -- |
| CBOT Soybeans | 1,674.25 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,818.83 | 0.07%Negative |
| Euro STOXX 50 | 3,514.32 | 0.99%Negative |
| FTSE 100 | 7,312.32 | 0.15%Negative |
| Nikkei 225 | 26,804.60 | -- |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes